Drugs / VIB1116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04948099 | Jul 2021 → Jul 2023 | — | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIB1116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04948099 ↗ |
| Route | Intravenous | “Single dose of VIB1116, SC or IV administration.” NCT04948099 ↗ |
| Route | Subcutaneous | “Single dose of VIB1116, SC or IV administration.” NCT04948099 ↗ |